Topic

All

30
May
2024

Recognizing 11 Asian-American Executives Shaping the Future of Biopharmaceuticals

As we celebrate the end of AAPI Heritage Month, we acknowledge the vital role that Asian American and Pacific Islander professionals have made in the biopharmaceutical industry. We are honored to present an update to our 2021 feature on 11 AAPI professionals shaping the future of biopharma, again selected for their commitment to solving health problems, integrity in leadership, and...
Read More
26
May
2024

The Tao of Drucker: Lessons For Drug Developers from GLP-1

The two broad categories of medical discovery that command the most attention are insights resulting from rare, informative genetic conditions (see here) and advances resulting from fortuitous observations.   A canonical example of the value of extreme genetic phenotypes is the patient with familial hypercholesterolemia who inspired Brown and Goldstein’s scientific pursuit of cholesterol metabolism and led to the statins. Similarly,...
Read More
20
May
2024

SynBio and AI for Discovery: David Younger and Randolph Lopez on The Long Run

Today’s guests on The Long Run are the co-founders of Seattle-based A-Alpha Bio — David Younger and Randolph Lopez. David is the CEO and Randolph is the chief technology officer. The company was founded in 2017 as a spinout from the University of Washington’s Institute for Protein Design. The company has built a platform for doing high-volume synthetic biology to...
Read More
20
May
2024

Timmerman Traverse Eclipses $10M for Cancer, Poverty, and Sickle Cell Disease

The Timmerman Traverse campaigns have now catalyzed the biotech community to give back more than $10 million to tackle cancer, poverty, and sickle cell disease. It’s a moment to celebrate. These biotech community drives have succeeded beyond my wildest dreams. They’ve raised awareness, corralled funds, and stitched together a network of meaningful relationships.   More than 120 people have become...
Read More
13
May
2024

Here’s The Skinny on Four New GLP-1 Podcasts

GLP-1 medicines are obviously having a real moment – medically and culturally.  These once-weekly injectables, which reduce appetite and result in significant, long-lasting (so long as you’re taking them…) weight loss, have been demonstrated to have a number of important health benefits beyond simply shedding pounds.  In March, Novo Nordisk’s semaglutide (Wegovy) was approved by the FDA for its ability...
Read More
4
May
2024

Success in Film and Pharma: Contingent But Not Random

Film and pharma, like many creative endeavors, exist in a world of power law economics, where a handful of exceptionally successful products account for a massively disproportionate share of the total revenue.  Consequently, in both domains, there’s a powerful incentive to “pick winners.” Every studio head and every R&D leader tries desperately to do this.  But there’s a problem: as...
Read More
1 2 3 71